ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Location: France, Provence-Alpes-Côte d'Azur, Marseille
Employees: 11-50
Total raised: $175.37M
Founded date: 2015
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.06.2022 | Series C | $100.5M | - |
| 04.12.2019 | Series B | $53M | - |
| 02.05.2017 | Series A | $21.87M | - |
Mentions in press and media 24
| Date | Title | Description |
| 17.02.2026 | Andera Partners strengthens its position among the leading players in private equity | Against an economic and financial backdrop marked in 2025 by a global slowdown and a sharp downturn in the private equity market – fund investments were down by more than 20% in France – Andera Partners is continuing to implement its strate... |
| 29.10.2025 | Earlybird Health promotes two new partners as firm deepens biotech and analytics focus | Life sciences investor Earlybird Health has promoted Dr. Rabab Nasrallah and Dr. Christoph Massner to Partners. Both new partners have led the firm's strategy across biotech, data-enabled therapeutics and medtech. Earlybird Health, part of ... |
| 24.10.2025 | Enpal secures €700M ABS facility, Lakestar calls time on generalist venture funds, and 15% of Slush alumni become founders | This week, we tracked more than 70 tech funding deals worth over €1.3 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most ... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion Wed, Oct 22, 2025 09:20 CET Report this content Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 22.10.2025 | Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics | Pharmaceutical company Ipsen has acquired ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ImCheck was founded in 2015 based on the research of Professor Daniel Olive, Direct... |
| 22.10.2025 | Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio, expanding its leadership in oncology, strengthening its pipeline | Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French ... |
| 10.10.2024 | Kurma Partners: First Closing Of €250 Million Biofund IV | Kurma Partners, an asset manager focused on improving human health, announced that it has raised EUR 140 million, completing the first closing of Biofund IV. By the final closing in 2025, Kurma aims to have raised a total of €250 million in... |
| 29.08.2024 | ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan | FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030 ambitious vision to deliver 20 innovative biome... |
| 17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals opportunities and gaps in investor and startups' commitments | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metrics, commitments, and actions from now to forever. Earlybird is one of Europe's most established and active Venture capital firms published ... |
| 13.06.2022 | ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunoth... | Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera Partners, Invus and patient organization The Leu... |
Show more